Article

Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysis

2023-04-11

Abstract excerpt

<title>Abstract</title> <p><bold>Introduction</bold>: The development of immune checkpoint inhibitors (ICIs) marked a revolutionary milestone in the immunotherapy of cancers. Although ICIs have shown survival benefits and potential clinical prospects, these drugs also triggered a myriad of autoimmune side effects, termed immune-related adverse events (irAEs). Notably, thyroid-related adverse events (AEs) are one...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 684b1cb2-9ad8-57c0-83a3-8321737b407c
DOI: 10.21203/rs.3.rs-2749138/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisDOI 10.21203/rs.3.rs-2749138/v1Read

Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective studySemantic proximity Read

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.Semantic proximity Read

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity Read

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read

Baseline risk factors associated with immune related adverse events and atezolizumabSemantic proximity Read

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in PolandSemantic proximity Read

Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.Semantic proximity Read

Toxicities of PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSemantic proximity Read

The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitorsSemantic proximity Read

Adverse events induced by immune checkpoint inhibitors.Semantic proximity Read

Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levelsSemantic proximity Read